Patents by Inventor Peter Diederik Jan Grootenhuis

Peter Diederik Jan Grootenhuis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
    Publication number: 20190076419
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: April 10, 2018
    Publication date: March 14, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina HADIDA RUAH, Peter Diederik Jan GROOTENHUIS, Fredrick F. VAN GOOR, Jinglan ZHOU, Brian Richard BEAR, Mark Thomas MILLER, Jason McCARTNEY, Mehdi Michel Djamel NUMA
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20190055220
    Abstract: The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: March 31, 2017
    Publication date: February 21, 2019
    Inventors: Brian Bear, Jeremy Clemens, Thomas Cleveland, Timothy Richard Coon, Peter Diederik Jan Grootenhuis, Bryan A. Frieman, Sara S. Hadida Ruah, Haripada Khatuya, Paul J. Krenitsky, Mark Thomas Miller, Alina Silina, Johnny Uy, Jinglan Zhou
  • Modulators of ATP-binding cassette transporters
    Patent number: 10022352
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 17, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida Ruah, Peter Diederik Jan Grootenhuis, Fredrick F. Van Goor, Jinglan Zhou, Brian Richard Bear, Mark Thomas Miller, Jason McCartney, Mehdi Michel Djamel Numa
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20180185364
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: August 11, 2017
    Publication date: July 5, 2018
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator
    Publication number: 20180162839
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 14, 2018
    Inventors: Alexander Russell Abela, Timothy Alcacio, Corey Anderson, Paul Timothy Angell, Minson Baek, Jeremy J. Clemens, Thomas Cleveland, Lori Ann Ferris, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Robert M. Hughes, Pramod Virupax Joshi, Ping Kang, Ali Keshavarz-Shokri, Haripada Khatuya, Paul John Krenitsky, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Jean Denis Pierre, Yi Shi, Muna Shrestha, David Andrew Siesel, Kathy Stavropoulos, Andreas P. Termin, Fredrick F. Van Goor, Johnny Uy, Timothy John Young, Jinglan Zhou
  • Modulators of ATP-binding cassette transporters
    Patent number: 9974781
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: May 22, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida Ruah, Peter Diederik Jan Grootenhuis, Fredrick F. Van Goor, Jinglan Zhou, Brian Richard Bear, Mark Thomas Miller, Jason McCartney, Mehdi Michel Djamel Numa
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 9782408
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: October 10, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20170196862
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: October 6, 2015
    Publication date: July 13, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Ciemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
    Publication number: 20170189389
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: August 11, 2016
    Publication date: July 6, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina HADIDA-RUAH, Peter Diederik Jan GROOTENHUIS, Fredrick F. VAN GOOR, Jinglan ZHOU, Brian Richard BEAR, Mark Thomas MILLER, Jason McCARTNEY, Mehdi Michel Djamel NUMA, Xiaoqing YANG
  • Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels
    Publication number: 20170145011
    Abstract: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 25, 2017
    Inventors: Sara Sabina HADIDA RUAH, Edward Adam KALLEL, Mark Thomas MILLER, Vijayalaksmi ARUMUGAM, Jason McCARTNEY, Corey ANDERSON, Peter Diederik Jan GROOTENHUIS, Licong JIANG
  • Modulators of ATP-binding cassette transporters
    Patent number: 9550761
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: January 24, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida-Ruah, Peter Diederik Jan Grootenhuis, Mark Thomas Miller, Matthew Hamilton
  • Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels
    Patent number: 9511067
    Abstract: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 6, 2016
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida Ruah, Edward Adam Kallel, Mark Thomas Miller, Vijayalaksmi Arumugam, Jason McCartney, Corey Anderson, Peter Diederik Jan Grootenhuis, Licong Jiang
  • MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
    Publication number: 20160271105
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: March 23, 2016
    Publication date: September 22, 2016
    Inventors: Sara Sabina HADIDA-RUAH, Peter Diederik Jan GROOTENHUIS, Fredrick F. VAN GOOR, Jinglan ZHOU, Brian Richard BEAR, Mark Thomas MILLER, Jason McCARTNEY, Mehdi Michel Djamel NUMA, Xiaoqing YANG, Nitin NAIR
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20160221952
    Abstract: This invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH2OH.
    Type: Application
    Filed: December 31, 2015
    Publication date: August 4, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Xiaoqing Yang, Sara Sabina Hadida Ruah, Peter Diederik Jan Grootenhuis, Fredrick F. Van Goor, Martyn Curtis Botfield, Gregor Zlokarnik
  • Benzoxazines as modulators of ion channels
    Patent number: 9365588
    Abstract: The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: June 14, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida-Ruah, Peter Diederik Jan Grootenhuis, Mark Thomas Miller, Corey Anderson, Joseph Pontillo, Edward Adam Kallel, Mehdi Michael Djamel Numa, Bryan A. Frieman, Jason McCartney, Jennings Franklin Worley, III, Vijayalaksmi Arumugam, Johnny Uy, Nicole Hilgraf, Brian Richard Bear
  • Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
    Publication number: 20160095858
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: October 6, 2015
    Publication date: April 7, 2016
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Khatuya Haripada, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdgogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20160022664
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 23, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20160022665
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Morpholine-spirocyclic piperidine amides as modulators of ion channels
    Patent number: 9181273
    Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: November 10, 2015
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida-Ruah, Hayley Marie Binch, Michael Paul DeNinno, Lev Tyler Dewey Fanning, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Nicole Hilgraf, Pramod Joshi, Edward Adam Kallel, Mark Thomas Miller, Joseph Pontillo, Alina Silina, Urvi Jagdishbhai Sheth, Dennis James Hurley, Vijayalaksmi Arumugam
  • Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels
    Publication number: 20150174127
    Abstract: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: December 22, 2014
    Publication date: June 25, 2015
    Inventors: Sara Sabina HADIDA RUAH, Edward Adam KALLEL, Mark Thomas MILLER, Vijayalaksmi ARUMUGAM, Jason McCARTNEY, Corey ANDERSON, Peter Diederik Jan GROOTENHUIS, Licong JIANG